MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer

Authors

  • Muhammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA

DOI:

https://doi.org/10.6092/1590-8577/2507

Keywords:

Carcinoma, Drug Therapy, Gemcitabine, Neoplasm Metastasis, Pancreas, Pancreatic Neoplasms, Therapeutics

Abstract

No abstract available.

Image: Tufts Medical Center Teddy Bear (Formerly F.A.O. Schwartz Teddy Bear). Boston, MA, USA.

Downloads

Download data is not yet available.

References

http://www.marketwatch.com/story/merrimack-pharmaceuticals-announces-mm-398-achieves-primary-endpoint-of-overall-survival-in-phase-3-trial-in-post-gemcitabine-metastatic-pancreatic-cancer-2014-05-01 (last assessed May 06, 2014)

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 16.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12; 364(19):1817-25.

Saif MW, Chabot J. Chemotherapy: Metastatic pancreatic cancer: is FOLFIRINOX the new standard? Nat Rev Clin Oncol 2011 Jul 5; 8(8):452-3.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47: 1676-81.

Tufts Medical Center. Boston, MA, USA

Downloads

Published

2014-05-27

How to Cite

Saif, M. W. (2014). MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer. JOP. Journal of the Pancreas, 15(3), 278–279. https://doi.org/10.6092/1590-8577/2507

Issue

Vol. 15 No. 3 (2014): May - p. 219-279

Section

PANCREAS NEWS

License

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.

Most read articles by the same author(s)

> >>